Understanding the “Three C’s” may provide the insights need to move the needle on the cancers with the bleakest prognoses.
When a result provides questionable or limited clinical utility, physicians and genetic counselors must educate patients and providers on the pros and cons of genetic testing.
New regimen offers a promising approach for unrelated donor transplants.
Characterization of GGAA-microsatellites provides insight in the role of noncoding DNA in cancer susceptibility and therapeutic development.
The Head Start 4 clinical trial introduces risk stratification and builds on the success of bone marrow transplantation for young children with malignant embryonal tumors.
Researchers describe how the association of the EWS/FLI transcription factor with GGAA-microsatellites drives Ewing sarcoma.
Despite guidelines that advocate watching and waiting, physicians are still treating most patients with immune thrombocytopenia.
